Sign In
Buy JAZZ
$230.25
+4.33 (+1.92%)
At Close: Jun 23, 2026
Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks
02:40pm, Tuesday, 23'rd Jun 2026
Zepzelca's failed trial doesn't derail Jazz's growth strategy. First-line adoption is becoming Zepzelca's biggest opportunity.
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies
11:31am, Thursday, 18'th Jun 2026
Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
12:54pm, Wednesday, 17'th Jun 2026
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation T-cell-engaging multispecific antibodies.
Jazz Pharma, AbCellera ink antibody deal worth up to $876 million
07:43am, Wednesday, 17'th Jun 2026
Jazz Pharmaceuticals has signed a research collaboration and licensing agreement with Canada's AbCellera to develop T-cell engaging multispecific antibodies for cancer, the companies said on Wed
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
07:00am, Wednesday, 17'th Jun 2026
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and AbCellera (Nasdaq: ABCL) today announced a preclinical research collaboration, option and license
New late-breaking data presentations underscore Jazz's significant progress in advancing holistic understanding of narcolepsy and idiopathic hypersomnia, including novel real-world evidence of meaning
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study
01:21pm, Monday, 15'th Jun 2026
Jazz Pharmaceuticals' Zepzelca fails a phase III lung cancer study, but strong first-line uptake and 2026 guidance remain unchanged.
Jazz Pharmaceuticals lung cancer drug fails main trial goal
08:53am, Friday, 12'th Jun 2026
Jazz Pharmaceuticals said on Friday its lung cancer drug Zepzelca failed to meet the main goal of improving overall survival in a late-stage study, potentially risking its current regulatory sta
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
08:00am, Friday, 12'th Jun 2026
For U.S. media and investors only DUBLIN, June 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 LAGOON trial, conducted by PharmaMar,
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
10:40am, Thursday, 11'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Jazz Pharmaceuticals' New Cancer Drug Drives $1.3 Billion Opportunity, Says Analyst
12:44pm, Wednesday, 10'th Jun 2026
Jazz Pharmaceuticals PLC's (NASDAQ:JAZZ) revenue growth and stock valuation is being driven by the adoption of Ziihera as a first-line (1L) treatment of HER2-positive (HER2+) metastatic gastroesophage
Why Is Jazz (JAZZ) Up 1% Since Last Earnings Report?
12:36pm, Thursday, 04'th Jun 2026
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia For U.S. media and investors onl
Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript
02:12pm, Wednesday, 03'rd Jun 2026
Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Momentum Stock
10:51am, Monday, 01'st Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
